CLINICAL TRIALS PROFILE FOR CYCLOPENTOLATE HYDROCHLORIDE
✉ Email this page to a colleague
All Clinical Trials for Cyclopentolate Hydrochloride
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00348166 ↗ | Does Undercorrection of Myopia Retard Myopia Progression Among Kindergarten Children? | Withdrawn | KK Women's and Children's Hospital | Phase 1 | 2005-12-01 | The purpose of this study is to find out if undercorrection of myopia slow down the progression of myopia in kindergarten children. |
| NCT01170130 ↗ | Lidocaine Usage for Pupil Dilatation (Mydriasis) | Completed | Carmel Medical Center | N/A | 2009-12-01 | The purpose of this study is to determine if the mydriatic effect of intracameral lidocaine 1% is as effective as topical cyclopentolate 1% and phenylephrine 10% for achieving effective mydriasis during phacoemulsification surgery. |
| NCT02177539 ↗ | A New More Efficient Cycloplegia Scheme | Unknown status | Pontificia Universidad Catolica de Chile | Phase 4 | 2014-05-01 | The purpose of this study is to determine whether tropicamide + phenylephrine cyclopentolate + applied for once waiting 30 minutes to retinoscopy (new scheme) is not inferior to apply cyclopentolate alone and wait 45 minutes to retinoscopy (traditional scheme) |
| NCT02309385 ↗ | Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis | Completed | National Eye Institute (NEI) | Phase 1/Phase 2 | 2014-10-01 | The purpose of this study is to determine the efficacy, safety, and tolerability of dexamethasone sodium phosphate Visulex (DSP-Visulex) after repeated-dose administration in patients with acute anterior uveitis. |
| NCT02309385 ↗ | Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis | Completed | Aciont Inc | Phase 1/Phase 2 | 2014-10-01 | The purpose of this study is to determine the efficacy, safety, and tolerability of dexamethasone sodium phosphate Visulex (DSP-Visulex) after repeated-dose administration in patients with acute anterior uveitis. |
| NCT02895035 ↗ | Comparison of Epinephrine and Phenylephrine/Ketorolac With Regards to Pupil Size | Terminated | Milton S. Hershey Medical Center | Phase 4 | 2016-09-01 | The objective of this study is to compare the maintenance of intraoperative mydriasis during cataract surgery between two drugs: epinephrine, which has routinely been used for decades, and Omidria, a newly FDA approved combination drug of phenylephrine and ketorolac. Patients undergoing cataract surgery that are enrolled in the trial will randomly receive one of the drugs in one eye, and the other eye will receive the drug during the subsequent cataract surgery. |
| NCT03508817 ↗ | Atropine 0.01% Eye Drops in Myopia Study | Enrolling by invitation | Christian Medical College, Vellore, India | Early Phase 1 | 2018-12-20 | Control of myopia progression has become an important goal because of concerns regarding significantly increased risks of retinal degeneration, retinal detachment, glaucoma and cataract associated with high myopia. It is also clear there prevalence of myopia in children and young adults is increasing all over the world. Several methods including use of progressive addition lenses, rigid gas-permeable contact lenses, and life-style modifications (increased outdoor activity) have reported to alter myopia progression with varying efficacy. In general they have yielded clinical results of marginal significance. Atropine sulphate eye drops has consistently been demonstrated to inhibit axial myopia progression in both humans and animal models. Yet it has not found widespread clinical application for myopia control due to ocular side-effects of cycloplegia and pupil dilation. Recently 0.01% atropine has been shown to be effective in arresting myopia progression without side-effects of cycloplegia and near vision impairment and pupil dilatation and increased light sensitivity. Almost all studies on atropine have been carried out on children of Chinese origin. Efficacy (concentration and dosing) and safety need to be established in the population of interest, before routine use can be recommended. We plan to evaluate the efficacy and safety of topical 0.01% atropine eye drops in slowing the progression of myopia and ocular axial elongation in Omani children. A total of 150 children of ages 6-16 years will be randomized to two groups. Intervention group will receive atropine 0.01% once daily in each eye for two years (Phase 1). Control group will not receive any medications. Follow up visits will be scheduled every three months in Phase 1. Subsequently, medication will be stopped and the study patients will be followed up every six months for one year (Phase 2). The progression of myopia (change in refractive error and axial length) will be compared in the two groups by objective methods. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Cyclopentolate Hydrochloride
Condition Name
Clinical Trial Locations for Cyclopentolate Hydrochloride
Trials by Country
Clinical Trial Progress for Cyclopentolate Hydrochloride
Clinical Trial Phase
Clinical Trial Sponsors for Cyclopentolate Hydrochloride
Sponsor Name
